Literature DB >> 16430192

Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.

Frederick Hayden1, Alexander Klimov, Masato Tashiro, Alan Hay, Amold Monto, Jennifer McKimm-Breschkin, Catherine Macken, Alan Hampson, Robert G Webster, Michèle Amyard, Maria Zambon.   

Abstract

The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16430192

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  21 in total

1.  The use of antiviral drugs for influenza: recommended guidelines for practitioners.

Authors:  Upton D Allen; Fred Y Aoki; H Grant Stiver
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

2.  Antiviral activity of the effective monomers from Folium Isatidis against influenza virus in vivo.

Authors:  Zhao Liu; Zhan-qiu Yang; Hong Xiao
Journal:  Virol Sin       Date:  2011-01-10       Impact factor: 4.327

Review 3.  Theoretical aspects of immunity.

Authors:  Michael W Deem; Pooya Hejazi
Journal:  Annu Rev Chem Biomol Eng       Date:  2010       Impact factor: 11.059

4.  Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.

Authors:  Robert W Sidwell; Dale L Barnard; Craig W Day; Donald F Smee; Kevin W Bailey; Min-Hui Wong; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

5.  Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS.

Authors:  Niklas Lindegardh; Warunee Hanpithakpong; Benjamas Kamanikom; Jeremy Farrar; Tran Tinh Hien; Pratap Singhasivanon; Nicholas J White; Nicholas P J Day
Journal:  Bioanalysis       Date:  2011-01       Impact factor: 2.681

Review 6.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

7.  Identification of PTCH1 requirement for influenza virus using random homozygous gene perturbation.

Authors:  Wu-Bo Li; Jie Zhu; Brit Hart; Baoquan Sui; Ke Weng; Shaojing Chang; Rebecca Geiger; Montserrat Torremorell; Alan Mileham; Christy Gladney; Martha A Mellancamp; Limin Li; Abdul Yunus; Michael Goldblatt; Michael S Kinch
Journal:  Am J Transl Res       Date:  2009-04-12       Impact factor: 4.060

8.  Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity.

Authors:  Shin-Ru Shih; Tzu-Yun Chu; Gadarla Randheer Reddy; Sung-Nain Tseng; Hsiun-Ling Chen; Wen-Fang Tang; Ming-sian Wu; Jiann-Yih Yeh; Yu-Sheng Chao; John Ta Hsu; Hsing-Pang Hsieh; Jim-Tong Horng
Journal:  J Biomed Sci       Date:  2010-02-23       Impact factor: 8.410

9.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 10.  Avian influenza virus (H5N1): a threat to human health.

Authors:  J S Malik Peiris; Menno D de Jong; Yi Guan
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.